<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536625</url>
  </required_header>
  <id_info>
    <org_study_id>RAPANK</org_study_id>
    <nct_id>NCT02536625</nct_id>
  </id_info>
  <brief_title>Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)</brief_title>
  <acronym>RAPANK</acronym>
  <official_title>RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Biostatistics and Therapy Evaluation Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NK (Natural Killer) cells are important in the fight against tumor, especially for the
      control of cancer metastasis. The purpose of this prospective study is to evaluate the impact
      on lymphocytes NK functions and development of an everolimus treatment in women treated for a
      metastatic breast cancer. In particular, the study of lymphocytes NK functions and
      development under everolimus treatment could permit to validate an early biomarker of the
      impact of everolimus on these NK cells.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the level of Granzyme B (GzmB)</measure>
    <time_frame>Timepoint at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The objective response rate (ORR) will be defined as the proportion of patients (described on the efficacy-evaluable population) who achieve complete response (CR) or partial response (PR). ORR is based on tumor assessments (measurements according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Measured from the date of study drugs start to the date of the first objective radiological disease progression using RECIST 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the duration of time from start of treatment to time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intercurrent diseases reporting</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with adverse events (including infectious events) related to everolimus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating NK functions</measure>
    <time_frame>Timepoint at 3 months and at 9 months</time_frame>
    <description>Characterization of circulating NK functions by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTOR activation status</measure>
    <time_frame>Timepoint at 3 months and at 9 months</time_frame>
    <description>rpS6 phosphorylation rate by western blot</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <description>Immunomonitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prospective study</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative) eligible for a treatment
        with everolimus in this application
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &gt; 18 years old

          -  Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human
             Epidermal Growth Factor Receptor-2)

          -  ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2

          -  Eligible to an hormonotherapy treatment combined to an mTOR (mammalian Target Of
             Rapamycin) inhibitor (i.e. SPC (Summary of Product Characteristics) modalities)

          -  Measurable disease according to RECIST 1.1 (Response Evaluation Criteria In Solid
             Tumors)

          -  Not receiving the non-authorized concomitant treatments

          -  Patient should understand, sign, and date the written voluntary informed consent form
             at the screening visit prior to any protocol-specific procedures performed.

          -  Patients must be covered by a medical insurance

        Exclusion Criteria:

          -  BMI&gt;30

          -  All dysimmune disease, history of transplantation or immunosuppressive therapy or
             corticotherapy

          -  All chronic inflammatory diseases

          -  Last chemotherapy &lt; 6 months

          -  Corticotherapy &lt;1 year and more than 1 month

          -  Restrictive diet ≤3 months before inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TREDAN Olivier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>NK</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

